Edwards Lifesciences (EW) Cash from Investing Activities (2009 - 2026)

Edwards Lifesciences' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$92.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 208.79% year-over-year to -$92.8 million; the TTM figure through Mar 2026 stood at -$891.0 million (down 138.16% YoY), while the FY2025 annual figure was -$712.9 million, down 130.82% from the prior year.
• Cash from Investing Activities was -$92.8 million for Q1 2026 at Edwards Lifesciences, up from -$198.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $2.7 billion in Q3 2024 to a low of -$576.7 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged $113.7 million across 5 years, with a median of $63.1 million in 2024.
• Biggest YoY gain for Cash from Investing Activities was 12520.0% in 2024; the steepest drop was 4190.07% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $94.7 million in 2022, then tumbled by 85.11% to $14.1 million in 2023, then sank by 4190.07% to -$576.7 million in 2024, then surged by 65.61% to -$198.3 million in 2025, then surged by 53.2% to -$92.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$92.8 million (Q1 2026), -$198.3 million (Q4 2025), and -$427.8 million (Q3 2025), per Business Quant data.